First Short-Acting Insulin Approved as a "Follow-On" Product

By December 11, 2017

The use of abbreviated pathways can reduce drug development costs so products can be offered at a lower price to patients.

Following Gastric Bypass, Nature of β-Cell Sensitivity May Change

December 11, 2017

During the highest dose of glucose infusion, the GB subjects had relative hyperglycemia associated with significantly reduced β-cell glucose sensitivity throughout both step-up

Intervention Demonstrates Significant T2D Remission in Primary Care

December 06, 2017

A total of 306 individuals aged 20 to 65 years who had been diagnosed with type 2 diabetes in the past 6 years, had a body mass index of 27 to 45kg/m², and were not receiving insulin were recruited.

Ozempic Approved to Treat Adults With Type 2 Diabetes

By December 05, 2017

The global Phase 3a clinical trial program for Ozempic comprised 8 clinical trials involving more than 8,000 adults with type 2 diabetes.

Does Antibiotic Use Increase the Risk of Diabetes?

December 05, 2017

The researchers found that while more cases than controls received at least 6 courses of antibiotics (17.9 versus 13.8%), the association between antibiotic use and risk of diabetes was progressively reduced when clinical and lifestyle factors were accounted for.

T2DM Treatment Adherence Compared Across Drug Classes

December 04, 2017

Adherence better for sulfonylureas and thiazolidinediones compared with metformin

HbA1c-Lowering Effects of DPP4i Therapy May Be Blunted by Diet

December 01, 2017

Multiple regression analyses revealed that fat intake, especially saturated fat intake, was significantly correlated with ΔHbA1c.

Severe Hypoglycemia and Absolute CV Risk Examined in Community Setting

December 01, 2017

Following severe hypoglycemia, the 3-year cumulative incidence of mortality was 28.3%, and that of coronary heart disease was 10.8%.

Possible Fungal Contamination Prompts Recall of Diabetes Drug Riomet

By November 27, 2017

The contamination was discovered during sample preparation for the Antimicrobial Preservative Effectiveness Testing.

New Consensus Report Defines Clinically Meaningful T1D Outcomes

By November 22, 2017

To address this issue, the Type 1 Diabetes Outcomes Program was launched to develop consensus definitions for a set of priority outcomes for T1D.

Higher β-Blocker Dose May Benefit CHF Patients With Diabetes

November 21, 2017

Effect is larger in chronic heart failure patients with diabetes than CHF patients without diabetes

SCS Beneficial for Patients With Painful Diabetic Peripheral Neuropathy

November 20, 2017

After 5 years, more than half of patients with painful diabetic polyneuropathy had treatment success

Body Surface Area Affected by Psoriasis May Be Linked to T2DM Risk

By November 20, 2017

To determine the risk of T2DM, researchers compared adults with psoriasis (n=8124), grouping them by affected BSA, to those without psoriasis (n=76,599); patients were followed for ~4 years.

Nationwide Trends of Glycemic Control May Have 'Plateaued'

November 16, 2017

The researchers found that glycemic control did not change between 2007-2008 and 2013-2014 overall or in any subgroup.

Antidiabetic Agents Compared in Patients With Diabetes and Heart Failure

By November 14, 2017

Data from the Duke University Health System (DUHS) electronic health records were used to identify patients with both diabetes and heart failure.

First Nationwide Study Examines Cardiac Mortality in Young With Diabetes

November 14, 2017

All individuals in Denmark aged 1-35 in 2000-09 and 36-49 in 2007-09 were included in the study.

Ranibizumab Plus Dexamethasone vs. Ranibizumab Alone in DME

November 13, 2017

The researchers found that the mean improvement in visual acuity from randomization was 2.7 and 3 letters in the combination and ranibizumab groups, with the adjusted treatment group difference of −0.5 letters.

Serious Hypoglycemia Risk Compared Among Oral Antidiabetics

By November 07, 2017

Among all study drugs, the highest rate was seen with glyburide.

Experts Pick the Top 10 Medical Innovations for 2018

By November 03, 2017

The panel - made up of nearly 100 physicians and scientists - debated and whittled down over 150 nominations to decide upon the final 10.

New Data Show Canagliflozin May Improve Renal Outcomes in T2DM Patients

By November 03, 2017

The renal analyses showed that compared to placebo, canagliflozin reduced the risk of kidney disease progression, including significantly reducing urinary albumin excretion and stabilizing estimated glomerular filtration rate (eGFR) over a study duration of more than six years.

Elevated GLP-1 After Gastric Bypass May Improve Satiety

November 02, 2017

After Roux-en-Y, CNS activation reduced in response to food cues, GLP-1 levels significantly elevated We hypothesized that postoperative elevated GLP-1 levels contribute to the improved satiety regulation after RYGB via effects on the CNS.

ACE Inhibitor, Statin Tx Effects Assessed in Adolescents With T1D

November 02, 2017

Lower incidence of microalbuminuria was seen with use of an ACE inhibitor versus placebo; this was not considered significant in the context of negative findings for the primary outcome and statistical analysis plan.

Prognosis Assessed for Incretin Treated NOCS-Diabetes Patients

October 30, 2017

Among the diabetes patients, current incretin users had a significantly lower rate of all-cause death, cardiac death, and readmission for ACS through the 12-month period.

'Type 3c' Diabetes Often Mislabeled as Type 2

By October 25, 2017

The data showed diabetes following pancreatic disease was more common than type 1 diabetes (2.59 [95% CI: 2.38-2.81] per 100,000 person-years vs. 1.64 [95% CI: 1.47-1.82]; P<0.001). These cases of diabetes following pancreatic disease (n=559) were primarily classified by clinicians as type 2 diabetes.

VA/DoD: Recommendations for the Management of Type 2 Diabetes Mellitus

October 25, 2017

Patients should be offered individualized diabetes self-management education, as well as individualized glycemic management plans and target ranges for HbA1c.

Statin Use May Up Diabetes Risk in Higher Risk Patients

October 24, 2017

Researchers assessed incident diabetes by annual 75g oral glucose tolerance testing and semiannual fasting glucose among 3,234 participants enrolled in the Diabetes Prevention Program Outcomes Study.

Most Common Death Causes Among T2D Patients Investigated

October 24, 2017

Twenty-seven percent of CV deaths in diabetes patients with atherosclerotic CVD are categorized as sudden death.

Bydureon BCise Gets FDA Approval for Type 2 Diabetes

By October 23, 2017

In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a sulfonylurea, a thiazolidinedione, or any combination of two of these agents, at 28 weeks.

FDA Committee Supports Semaglutide Approval for Type 2 Diabetes

By October 19, 2017

The FDA Committee's positive recommendation was based on data from the global development program, SUSTAIN, which evaluated the safety and efficacy of once-weekly semaglutide.

Risk Factor of Progressing to Diabetes Varies by Intervention

October 18, 2017

The researchers found that 11 of the variables measured at baseline predicted progression to DM and 6 predicted regression to NGR.